Clinical trial

Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)

NCT03934931

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-07-13

PhaseNA

Study timeline

Study start (actual)2020-07-13Date precision: day

Registry last updated2025-05-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Tuberculosisunresolved

Latent Tuberculosisunresolved

HIV/AIDSunresolved

Interventions

Streamlined weekly DOT visitsOTHER

Weekly DOT visit remindersOTHER

Cost reimbursement DOTOTHER

Weekly SAT dosing reminders/check-insOTHER

Cost reimbursement SATOTHER

Sponsors & collaborators

University of California, San Franciscolead sponsor

Makerere Universitycollaborator

Johns Hopkins Bloomberg School of Public Healthcollaborator

University of Colorado, Denvercollaborator

National Heart, Lung, and Blood Institute (NHLBI)collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03934931 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.